Author

I. Solaroglu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

T. Bagci-Onder· 2 shared A. Cingoz· 1 shared A. Dansik· 1 shared A. Kayabolen· 1 shared A. Kusoglu· 1 shared A. P. Cribbs· 1 shared B. Isik· 1 shared C. Uzun· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

T. Bagci-Onder

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Extracellular matrix sulfation in the tumor microenvironment stimulates cancer stemness and invasiveness

A. Kusoglu, D. Ornek, A. Dansik, C. Uzun, S. N. Ozkan, S. Sarica, K. Yangin, S. Ozdinc, D. Turan Sorhun, N. Solcan, E. C. Doganalp, O. Arlov, K. Cunningham, I. C. Karaoglu, S. Kizilel, , E. Ozturk

The paper shows that increased sulfation in tumor ECM promotes cancer stemness and invasiveness through FAK-PI3K-mTOR signaling and RTK activation.

bioRxiv · Oct 17, 2023Bioengineering

Chronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibition

N. Pinarbasi Degirmenci, I. Sur-Erdem, V. Akcay, Y. Bolukbasi, U. Selek, I. Solaroglu, T. Bagci-Onder

This study shows that glioblastoma cells surviving chronic radiation upregulate DNA repair genes and are less sensitive to Chk1 inhibition, especially under hypoxia.

bioRxiv · Apr 16, 2022 · PreprintCancer Biology

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology